SP Group (SPG) Q1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2024 earnings summary
9 Nov, 2026Executive summary
Q1 revenue rose 2.2% YoY to DKK 722.9m; EBITDA increased 16.2% to DKK 148.4m, and EBT rose 23.8% to DKK 84.8m.
Organic growth in local currencies was 2.8%; currency movements reduced revenue by DKK 4.4m, or 0.6%.
Financial highlights
EBIT increased 26.2% YoY to DKK 98.6m; net income was DKK 66.4m versus DKK 53.7m, and diluted EPS rose 23.8% to DKK 5.47.
Operating cash flow was DKK 121.3m versus DKK 130.4m a year earlier; investing cash flow was negative DKK 29.2m and financing cash flow negative DKK 84.1m.
Equity including minorities was DKK 1,535.7m, up DKK 72.1m from year-end 2023; net interest-bearing debt was DKK 946.4m at March-end.
Outlook and guidance
FY 2024 guidance was maintained: revenue growth of 5–15%, EBITDA margin of 16–19%, and EBT margin of 9–12%.
Depreciation is expected to be slightly above 2023; financial expenses are expected at a similar level. A high investment level is planned for 2024.
Improving order intake and new healthcare, cleantech, and food-related products are expected to support profitable growth in coming quarters.
Latest events from SP Group
- Guidance held despite softer Q1 demand and heightened macroeconomic uncertainty.SPG
Q2 2023 - Earnings weakened, but guidance held as cleantech growth and new projects offered support.SPG
Q3 2023 - Lower 2023 earnings, stronger operating cash flow, and cautious growth guidance for 2024.SPG
Q4 2023 - Own-brand growth lifted H1 earnings and supported higher FY2024 guidance amid uncertainty.SPG
Q2 2024 - Own-brand growth lifted 9M EBITDA 38.1%; FY revenue growth guidance is 10–16%.SPG
Q3 2024 - Record revenue and margin growth in 2024, with strong outlook for 2025.SPG
Q4 2024 - H1 2025 saw lower sales and earnings, but margins and full-year outlook remain stable.SPG
Q2 2025 - Own-brand growth lifted 9M earnings as FY revenue guidance narrowed to 10%-16%.SPG
Q3 2024 - Q1 2025 saw 8.8% revenue growth, strong margins, and robust Healthcare segment gains.SPG
Q1 2025